How can we help you?
The latest from MDFA
Support life-changing research
Your donations make MDFA the largest non-government source of macular disease research funding in Australia. Donate to our tax appeal to help support life-changing research.
Macular Disease Foundation Australia awards $1 million to eight exciting research projects
Macular Disease Foundation Australia (MDFA) has awarded more than $1 million in research funding to eight promising projects, in a ceremony marking 10 years of significant advances in the search for a cure to Australia’s leading cause of blindness.
Inaugural Ita Buttrose Oration
MDFA Patron Ita Buttrose AC OBE calls on Government to reject Medicare eye injection rebate cut.
Macula Month focus on diabetes
Too many Australians have their eyes closed to diabetic retinopathy – the leading cause of blindness among our working-age population, a new study released for Macula Month (1-31 May) has revealed.
Macula Month
May is Macula Month, our annual awareness campaign to help Australians understand their risk of macular diseases and take early action to save their sight.
Ita Buttrose Oration
Ita will be the keynote speaker at this inaugural oration. She will address the big issues relating to eye health and vulnerable older Australians who are at risk of blindness.
Vision Voice: autumn 2021
This newsletter leads with the Aged Care Royal Commission’s recommendation to make aids and equipment more accessible for older Australians – a major win for our community.
MBS Ophthalmology Taskforce Review
A proposal to cut Medicare rebates for eye injections is the next big issue we’re tackling on behalf of our community.
Geographic atrophy in dry age-related macular degeneration
This webinar will touch on what geographic atrophy is and the role it plays in dry age-related macular degeneration.
Macular disease is the leading cause of blindness and severe vision loss in Australia. Early action saves sight. Find out about age-related macular degeneration, diabetic eye disease and other macular conditions.
Learn More
